QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease

Abstract Parkinson’s disease is one of the most common neurodegenerative illnesses in older persons and the leucine-rich repeat kinase 2 (LRRK2) is an auspicious target for its pharmacological treatment. In this work, quantitative structure–activity relationship (QSAR) models for identification of putative inhibitors of LRRK2 protein are developed by using an in-house chemical library and several machine learning techniques. The methodology applied in this paper has two steps: first, alternative subsets of molecular descriptors useful for characterizing LRRK2 inhibitors are chosen by a multi-objective feature selection method; secondly, QSAR models are learned by using these subsets and three different strategies for supervised learning. The qualities of all these QSAR models are compared by classical metrics and the best models are discussed in statistical and physicochemical terms.

[1]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[2]  Gustavo Henrique Goulart Trossini,et al.  Use of machine learning approaches for novel drug discovery , 2016, Expert opinion on drug discovery.

[3]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[4]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[5]  Mark R Cookson,et al.  LRRK2 Pathways Leading to Neurodegeneration , 2015, Current Neurology and Neuroscience Reports.

[6]  Andrew B West,et al.  G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons , 2016, The Journal of Neuroscience.

[7]  Ignacio Ponzoni,et al.  QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinson's Disease Using Cheminformatics Approaches , 2018, PACBB.

[8]  Víctor Sebastián-Pérez,et al.  Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. , 2017, European journal of medicinal chemistry.

[9]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Paul J Gilligan,et al.  Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease. , 2015, Current topics in medicinal chemistry.

[11]  Scott Boyer,et al.  Choosing Feature Selection and Learning Algorithms in QSAR , 2014, J. Chem. Inf. Model..

[12]  Anthony A Estrada,et al.  Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. , 2015, Journal of medicinal chemistry.

[13]  Fiorella Cravero,et al.  Hybridizing Feature Selection and Feature Learning Approaches in QSAR Modeling for Drug Discovery , 2017, Scientific Reports.

[14]  R. Aalizadeh,et al.  3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods , 2016, SAR and QSAR in environmental research.

[15]  Mati Karelson,et al.  Topological Fingerprints as an Aid in Finding Structural Patterns for LRRK2 Inhibition , 2014, Molecular informatics.